-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Hepatitis B Virus (HBV)
CAS No. | Product Name | Inquiry |
---|---|---|
569658-79-3 |
Libivirumab |
|
569658-80-6 |
ExbivirumabExbivirumab is a human monoclonal antibody that targets hepatitis B surface antigen. Exbivirumab has the potential for the treatment of hepatitis B infections. |
|
57378-72-0 |
Isochlorogenic acid CIsochlorogenic acid C is extracted from the flower bud of Lonicera japonica Thunb. Isochlorogenic acid C is a selective inhibitor of human immunodeficiency virus type 1 integrase. It has antioxidant activity. |
|
776-86-3 |
IsoscopoletinIsoscopoletin is a natural coumarin found in the herbs of Paederia scandens (Lour.) Merr. |
|
840529-13-7 |
Helioxanthin 8-1Helioxanthin 8-1 is an analogue of helioxanthin, which exhibites significant in vitro anti-HBV/HCV/HSV-1/HIV activity. It showed the most potent antiHBV activity among those helioxanthin analogues tested. It exhibited moderately potent activity against HIV and effective inhibition on DHBV replication. It would therefore be promising to study helioxanthin analogues that contain a six-membered ring instead of the five-membered ring found in the lactam. |
|
84638-48-2 |
(3R)-5,7-Dihydroxy-3-(4-hydroxybenzyl)-6-methyl-2,3-dihydro-4H-1-benzopyran-4-one(3R)-5,7-Dihydroxy-3-(4-hydroxybenzyl)-6-methyl-2,3-dihydro-4H-1-benzopyran-4-one is found in Dracaena cochinchinensis. |
|
911208-73-6 |
Tenofovir exalidexTenofovir exalidex, also known as HDP-Tenofovir and CMX-157, is a highly potent prodrug of the antiviral tenofovir, appeared safe and well-tolerated in patients with hepatitis B, according to a presentation at The Liver Meeting 2017. Tenofovir exalidex results in decreased circulating levels, lowering systemic exposure and thereby reducing the potential for renal and bone side effects. |
|
92562-88-4 |
LagociclovirLagociclovir is a prodrug of 3'-fluoro-2',3'-dideoxyguanosine with high oral bioavailability in humans and potent activity against HBV. |
|
92586-35-1 |
AZT triphosphateAZT triphosphate, an active triphosphate metabolite of Zidovudine (AZT), shows anti-retroviral activity, inhibits HIV replication, and also inhibits HBV DNA polymerase. It activates mitochondrial mediated apoptosis pathway. |
|
942123-43-5 |
Inarigivir soproxilInarigivir soproxil is an orally active agonist of innate immunity that works via the RIG-I and NOD2 pathways. Inarigivir soproxil exhibits broad-spectrum antiviral activity against resistant HCV variants. |
|
957011-15-3 |
HBF-0259HBF-0259 is a potent and selective hepatitis B virus (HBV) surface antigen (HBsAg) secretion inhibitor, with an EC50 of 1.5 μM in HepG2.2.15 cells. It has no effect on HBV DNA synthesis. |
|
960527-22-4 |
Isothiafludine |
|
99-93-4 |
Paracetamol EP Impurity EAn impurity of Paracetamol, a medication for the treatment of pain. |
|
98-92-0 |
NicotinamideNicotinamide, a water-soluble vitamin, is an active component of coenzymes NAD and NADP, and also acts as an activator of sirtuins. |
|
67-03-8 |
Thiamine hydrochlorideThiamine or vitamin B1 is a water-soluble vitamin of the B complex, its phosphate derivatives are involved in many cellular processes. |
|
142217-69-4 |
EntecavirAn oral antiviral drug used in the treatment of hepatitis B infection. A guanine analogue that inhhibits all three steps in the viral replication process. |
|
1228585-88-3 |
GS 9620GS 9620 is a potent and oral agonist of TLR7. |
|
887686-02-4 |
OSS-128167OSS-128167 is a selective SIRT6 inhibitor (IC50 = 89 µM). |
|
64938-51-8 |
Schisantherin CSchisantherin C is found in Kadsura longipedunculata, which has effect in lowering the serum glutamic-pyruvic transaminase level of the patients suffering from chronic virus hepatitis. |
|
65995-64-4 |
PunicalinPunicalin is an ellagitannin. It is a highly active carbonic anhydrase inhibitor with strong antioxidative activity. Punicalin have anti-hepatotoxic activity but the larger dose of punicalin induced liver damage. |
What is Hepatitis B virus (HBV)?
Hepatitis B virus (HBV) is the pathogen that causes hepatitis B and belongs to Hepadnaviridae family, which includes two genera, orthohepatophilic DNA virus and avian hepatotropic DNA virus, and it is orthohepatotropic DNA virus that causes human infection. HBV infection is a global public health problem, and hepatitis B infection is endemic worldwide, but the epidemic intensity of hepatitis B infection varies greatly in different regions, most of which occur in children and young adults, and a small number of patients can later transform into cirrhosis or liver cancer. According to the World Health Organization, about 2 billion people worldwide have been infected with hepatitis B, of which 350 million are chronically infected with hepatitis B, and about 1 million people die each year from liver failure, cirrhosis and primary hepatocellular carcinoma caused by hepatitis B infection.
Hepatitis B virus genotypes
The HBV genome has a unique and precise structure, about 3.2 kb long, composed of partial double-stranded DNA (rcDNA), and the four open reading frames (ORFs) are all located in the long strands, which are S, C, P, and X, among which the S region is completely chimeric in the P region, 23% and 39% of the C and X regions overlap with the P region, and the C region and X region overlap 4~5%, and the ORF overlap makes the utilization rate of the HBV genome as high as 150%. The S zone was divided into three coding regions: pre-S1, pre-S2 and S, which encoded pre-S1 protein, pre-S2 protein (pre-S2) and HBsAg, respectively. The C region is composed of the pre-C gene and the C gene, which encode HBeAg and HBcAg. The P region encodes a variety of functional proteins, including DNA polymerase and RNase H with reverse transcription activity, which are involved in the replication of HBV. The X gene encodes the X protein, which is HBxAg.
Fig.1 The genome of Hepatitis B virus. (Carreno Vicente, et al., 2006)
Hepatitis B virus structure
The mature hepatitis B virus is spherical in shape and has a lipid envelope with a diameter of about 42 nM. The HBV genome encodes large (L), medium (M), and small (S) hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg), hepatitis B core antigen (HBcAg), polymerase, and hepatitis B X protein (HBx). Hepatitis B virus has a bilayer capsid structure, the outer capsid is similar to the envelope of ordinary viruses, which is composed of a lipid bilayer and a protein, and HBsAg protein is embedded in the lipid bilayer. The core particle is icosahedral stereo symmetrical, and the surface of the core particle is the true capsid of the virus, which is composed of HBcAg of hepatitis B virus, and the central part is a circular and notched DNA duplex and a DNA polymerase attached to it. The length of the two strands of hepatitis B virus DNA is different, and the length of the long strand is constant and negative. The length of the short chain is variable, and it is a positive chain, and the length is about 50%~80% of the long chain (Fig.1).
Fig.2 Schematic diagram of hepatitis B virus (HBV) particles. (Herrscher Charline, et al., 2020)
Hepatitis B virus life cycle
The life cycle of HBV is as follows: First, HBV binds to the NTCP receptor and infects hepatocytes. The HBV nucleocapsid is then transported to the nucleus, and the rcDNA enters the nucleus and integrates into the human genome. The rcDNA is then converted into stable cccDNA by the host factor. cccDNA is used as a template to transcribe viral RNA. These viral RNAs are then translated into HBV proteins. At the same time, the pgRNA linked to the HBV polymerase is packaged into capsid particles. Using pgRNA as a template, the virus generates negative strands of DNA by reverse transcription, and further generates positive strands of DNA. Eventually, HBV viral particles and non-infectious subviral particles are formed and secreted.
Fig.3 Lifecycle of Hepatitis B virus. (Asselah Tarik, et al., 2019)
Hepatitis B virus spread routes
Blood-borne transmission: This is the main mode of transmission. These include unclean injections (e.g., intravenous drug users sharing syringes), acupuncture, transfusions of blood and blood products containing hepatitis virus, surgery, tooth extractions, hemodialysis, organ transplants, etc. Although you are now subjected to rigorous screening when you go to donate blood, it does not screen for HBsAg negative HBV carriers.
Mother-to-child transmission: It is mainly transmitted through the placenta, birth canal, breastfeeding and feeding. With improved sanitation technology and the combination of hepatitis B vaccine and hepatitis B immunoglobulin, mother-to-child transmission is now rare.
Sexual transmission: Unprotected sexual contact with an HBV-positive person, especially one with multiple sexual partners, is associated with a high risk of HBV infection.
Close contact transmission: Because HBsAg can be detected in the saliva, sweat, etc., close contact in life may be a special form of blood-borne transmission due to minor trauma.
Immunity to Hepatitis B virus
Hepatitis B virus (HBV) can cause abnormalities in the body's antiviral immune response through a variety of mechanisms, leading to persistent infection. Dendritic cells (DCs) are one of the full-time APCs, which can induce HBV-specific CD8+ T cells to eliminate viruses through cellular immune responses, and DC cells can also secrete type I interferon and proinflammatory factors to regulate immune function. The human body mainly clears hepatitis B virus through adaptive immune response, and hepatitis B virus-specific CD8+ T cells can directly kill hepatitis B virus-infected hepatocytes through cytotoxicity, but its main antiviral function is to secrete and produce IFNγ, TNFα, IL-2 and other cytokines, and inhibit the expression and replication of hepatitis B virus genes. Clearance of HBV infection depends on the number of HBV-specific CD8+ T cells with multiple secretory and killing functions.
Prevention and treatment of hepatitis B virus
Hepatitis B virus prophylaxis
Management of the source of infection: Patient registration, statistics, and guidance on disinfection, isolation and prevention for the patient's family.
Cut off the route of transmission: Pay attention to personal hygiene, keep toothbrushes, razors and other utensils from others, and do not share razors, toothbrushes and other supplies.
Protect susceptible populations: Hepatitis B vaccination is the most effective protection against HBV infection.
Hepatitis B virus treatment
Since 2010, when a significant clinical breakthrough was made in direct antiviral drugs targeting HIV and hepatitis C virus, the global research and development of chronic hepatitis B treatment drugs has begun to be active, especially anti-hepatitis B virus drugs with new mechanisms include capsid inhibitors, RNA interference drugs, Immune agonists and therapeutic vaccines have attracted the layout of many pharmaceutical companies and scientific research institutes.
Acute hepatitis: Generally, it is a self-limited disease, about 95% of patients have sufficient rest, proper nutrition, generally use liver protection drugs, vitamin supplements, and generally do not need antiviral treatment.
Chronic hepatitis: There are currently two types of anti-HBV drugs on the market, interferon alpha (conventional interferon and pegylated interferon) and five nucleoside analogues, the latter including Lamivudine, Tibivudine, Entecavir, Adefovir and Tenofovir. In addition, it can also enhance the body's non-specific immune function through immunomodulatory methods (Thymus peptide α1) with few adverse reactions.
References
- Carreno, Vicente, et al., Hepatitis B Virus and Hepatitis C Virus: Molecular Biology and Diagnosis. Perspectives in Medical Virology 13 (2006): 109-139.
- Herrscher, Charline, et al., Hepatitis B virus entry into cells. Cells 9.6 (2020): 1486.
- Asselah, Tarik, et al., Targets and future direct-acting antiviral approaches to achieve hepatitis B virus cure. The Lancet Gastroenterology & Hepatology 4.11 (2019): 883-892.
※ Please kindly note that our services are for research use only.